Summary & Overview
CPT 90676: Rabies Vaccine, Intradermal Administration
CPT code 90676 designates an intradermal rabies vaccine product used to prevent rabies virus infection. As a targeted vaccine administration code, it matters nationally due to its role in pre-exposure and post-exposure prophylaxis strategies, public health preparedness, and travel medicine. Use of intradermal rabies vaccination can affect supply logistics, clinic workflows, and payer coverage decisions for immunization services.
Key payers addressed in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise national-level orientation to the clinical purpose of the code, the typical outpatient sites where the service is delivered, and the administrative context relevant to payers. The publication also summarizes benchmarks for utilization and reimbursement where available, highlights policy and coding updates that affect how the vaccine is billed, and provides clinical context for intradermal rabies immunization practice.
This piece is written for clinicians, revenue cycle managers, and policy analysts seeking a clear, national summary of CPT code 90676, what it represents, and what to consider when encountering this code in billing and coverage scenarios.
Billing Code Overview
CPT code 90676 represents a rabies vaccine administered intradermally, delivered into the top layers of the skin to provide active immunization against rabies virus infection. This service is a preventive immunization intervention intended to induce protective immunity.
Service Type: Vaccine administration — intradermal immunization
Typical Site of Service: Outpatient clinic, public health clinic, travel medicine clinic, or other ambulatory care settings
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical scenario involves an adult or pediatric patient presenting to an outpatient clinic, travel medicine clinic, public health department, or emergency department after a potential rabies exposure (for example, a bite or scratch from a wild or domestic animal or an animal of unknown rabies vaccination status). The clinician assesses exposure risk, documents wound care and tetanus status, and determines the need for rabies post‑exposure prophylaxis or pre‑exposure prophylaxis. For intradermal administration using 90676, the vaccine is delivered into the dermis in small volumes at specified sites, often as part of a multi‑dose regimen. The workflow includes informed consent, verification of vaccine lot and expiration, preparation of sterile intradermal technique, administration, observation for immediate adverse reactions, and documentation of vaccine product, lot number, dose, route (intradermal), and site. Billing for 90676 is performed after vaccine administration; associated services may include evaluation and management for exposure assessment and wound care. Typical sites of service are outpatient clinics, travel medicine clinics, urgent care centers, public health clinics, and emergency departments. Typical patient scenario: a 32‑year‑old traveler with a bat bite while overseas presents to an urgent care clinic within 24–48 hours; the clinician determines post‑exposure prophylaxis is indicated and administers an intradermal rabies vaccine dose represented by 90676 as part of the recommended schedule, with observation and documentation completed per local protocol.
Coding Specifications
| Modifier | Description |
|---|